A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin.

Clark A, Kuo MC, Newman S, Hirst P, Pitcairn G, Pickford M

Pharmaceutical research21 Feb 2008Cited by 20 (Europe PMC)

PMID18288448DOI10.1007/s11095-008-9547-xPepBankPUB-18288448

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialPharmacokinetics
In healthy volunteers, salmon calcitonin pharmacokinetic profiles did not differ significantly across powder and liquid aerosol formulations.
In plain wordsIn healthy volunteers, salmon calcitonin blood profiles did not differ significantly between powder and liquid aerosols.
Peptide
Calcitonin-salmon
Outcome
No significant changePharmacokinetic profiles across aerosols
Study
n = 16
Comparator
Other aerosol formulations
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · pulmonaryAs given in this study (human).
Source sentences
Summary
Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.
2 context sentences(design, population, supporting numbers)
Summary · context
Aerosols were delivered as part of a 4 way cross-over study to 16 healthy volunteers.
Summary · context
Miacalcin injection was used as the subcutaneous control.
Report a problemFND-1828844801
02HumanNon-randomized trialPharmacokinetics
In healthy volunteers, aerosol salmon calcitonin lung bioavailability relative to subcutaneous injection ranged from 11% to 18%.
In plain wordsIn healthy volunteers, aerosol salmon calcitonin lung bioavailability ranged from 11% to 18% of subcutaneous injection.
Peptide
Calcitonin-salmon
Outcome
Not applicableRelative lung bioavailability
Study
n = 16
Comparator
Subcutaneous injection
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · pulmonaryAs given in this study (human).
Measurements
Relative lung bioavailability
11 to 18%
versus subcutaneous injection
Source sentences
Summary
Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.
2 context sentences(design, population, supporting numbers)
Summary · context
Aerosols were delivered as part of a 4 way cross-over study to 16 healthy volunteers.
Summary · context
Miacalcin injection was used as the subcutaneous control.
Report a problemFND-1828844802
03HumanNon-randomized trialPharmacokinetics
In healthy volunteers, salmon calcitonin relative bioavailability based on peripheral lung dose ranged from 20% to 33%.
In plain wordsIn healthy volunteers, salmon calcitonin bioavailability based on peripheral lung dose ranged from 20% to 33% of injection.
Peptide
Calcitonin-salmon
Outcome
Not applicablePeripheral-dose relative bioavailability
Study
n = 16
Comparator
Subcutaneous injection
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · pulmonaryAs given in this study (human).
Measurements
Peripheral-dose relative bioavailability
20 to 33%
versus subcutaneous injection
Source sentences
Summary
Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.
2 context sentences(design, population, supporting numbers)
Summary · context
Aerosols were delivered as part of a 4 way cross-over study to 16 healthy volunteers.
Summary · context
Miacalcin injection was used as the subcutaneous control.
Report a problemFND-1828844803
04HumanNon-randomized trialPharmacokinetics
In healthy volunteers, salmon calcitonin lung bioavailability did not differ significantly across aerosol formulations.
In plain wordsIn healthy volunteers, salmon calcitonin lung bioavailability did not differ significantly across aerosol formulations.
Peptide
Calcitonin-salmon
Outcome
No significant changeLung bioavailability across aerosol formulations
Study
n = 16
Comparator
Other aerosol formulations
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · pulmonaryAs given in this study (human).
Source sentences
Summary
Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.
2 context sentences(design, population, supporting numbers)
Summary · context
Aerosols were delivered as part of a 4 way cross-over study to 16 healthy volunteers.
Summary · context
Miacalcin injection was used as the subcutaneous control.
Report a problemFND-1828844804
05HumanNon-randomized trialPharmacokinetics
In healthy volunteers, aerosol salmon calcitonin lung doses ranged from 53 to 88 microgm.
In plain wordsIn healthy volunteers, aerosol salmon calcitonin lung doses ranged from 53 to 88 microgm.
Peptide
Calcitonin-salmon
Outcome
Not applicableDelivered lung dose
Study
n = 16
Outcome group
Pharmacokinetics · Respiratory
Studied dose
Dose not stated · pulmonaryAs given in this study (human).
Measurements
Lung dose
53 to 88 microgm
aerosol
Source sentences
Summary
Lung doses of sCal ranged from 53 to 88 microgm, peripheral lung doses from 25 to 51 microgm.
2 context sentences(design, population, supporting numbers)
Summary · context
Aerosols were delivered as part of a 4 way cross-over study to 16 healthy volunteers.
Summary · context
Miacalcin injection was used as the subcutaneous control.
Report a problemFND-1828844805
06HumanNon-randomized trialPharmacokinetics
In healthy volunteers, peripheral lung doses of aerosol salmon calcitonin ranged from 25 to 51 microgm.
In plain wordsIn healthy volunteers, peripheral lung doses of aerosol salmon calcitonin ranged from 25 to 51 microgm.
Peptide
Calcitonin-salmon
Outcome
Not applicablePeripheral lung dose
Study
n = 16
Outcome group
Pharmacokinetics · Respiratory
Studied dose
Dose not stated · pulmonaryAs given in this study (human).
Measurements
Peripheral lung dose
25 to 51 microgm
aerosol
Source sentences
Summary
Lung doses of sCal ranged from 53 to 88 microgm, peripheral lung doses from 25 to 51 microgm.
2 context sentences(design, population, supporting numbers)
Summary · context
Aerosols were delivered as part of a 4 way cross-over study to 16 healthy volunteers.
Summary · context
Miacalcin injection was used as the subcutaneous control.
Report a problemFND-1828844806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.